sumatriptan has been researched along with prazosin in 21 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (14.29) | 18.2507 |
2000's | 10 (47.62) | 29.6817 |
2010's | 8 (38.10) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Huang, L; Humphreys, JE; Morgan, JB; Polli, JW; Serabjit-Singh, CS; Webster, LO; Wring, SA | 1 |
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Campillo, NE; Guerra, A; Páez, JA | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Chen, X; Lin, X; Skolnik, S; Wang, J | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Baez, M; Cohen, ML; Cushing, DJ; Kursar, JD; Schenck, K | 1 |
Centurión, D; De Vries, P; Rabelo, G; Sánchez-López, A; Saxena, P; Villalón, CM | 1 |
De Vries, P; Heiligers, JP; Saxena, PR; Trion, M; Villalón, CM; Willems, EW | 1 |
Chen, J; Purdy, RE; Yildiz, O | 1 |
Cordi, AA; Ragonnet, C; Vayssettes-Courchay, C; Verbeuren, TJ | 1 |
Bidouard, JP; Caille, D; Gautier, E; Grosset, A; Janiak, P; La Rochelle, CD; O'Connor, SE; Robineau, P | 1 |
Alanezi, KH; Cinà, CS; Safar, HA | 1 |
1 review(s) available for sumatriptan and prazosin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
20 other study(ies) available for sumatriptan and prazosin
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Rational use of in vitro P-glycoprotein assays in drug discovery.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Chromatography, Liquid; Enzyme Inhibitors; Fluoresceins; Fluorescent Dyes; Humans; Mass Spectrometry; Pharmacology; Spodoptera | 2001 |
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity | 2011 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Serotonin-induced contraction in canine coronary artery and saphenous vein: role of a 5-HT1D-like receptor.
Topics: 5-Methoxytryptamine; Adrenergic alpha-Antagonists; Animals; Base Sequence; Blotting, Southern; Coronary Vessels; Dioxanes; DNA Primers; Dogs; Dose-Response Relationship, Drug; Gene Expression; Idazoxan; Molecular Sequence Data; Muscle Contraction; Muscle, Smooth, Vascular; Piperazines; Polymerase Chain Reaction; Prazosin; Receptors, Serotonin; RNA, Messenger; Saphenous Vein; Serotonin; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1994 |
Canine external carotid vasoconstriction to methysergide, ergotamine and dihydroergotamine: role of 5-HT1B/1D receptors and alpha2-adrenoceptors.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Blood Flow Velocity; Carotid Arteries; Clonidine; Dihydroergotamine; Dogs; Ergotamine; Female; Hemodynamics; Male; Methysergide; Oxadiazoles; Phenylephrine; Piperazines; Prazosin; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Adrenergic, alpha-2; Receptors, Serotonin; Serotonin Antagonists; Sumatriptan; Vasoconstriction; Vasoconstrictor Agents; Yohimbine | 1999 |
Pharmacological evidence that alpha1-and alpha2-adrenoceptors mediate vasoconstriction of carotid arteriovenous anastomoses in anaesthetized pigs.
Topics: Anesthesia; Animals; Arteriovenous Anastomosis; Azepines; Carotid Arteries; Hemodynamics; Migraine Disorders; Oxadiazoles; Phenylephrine; Piperazines; Prazosin; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, alpha-2; Receptors, Serotonin; Sumatriptan; Swine; Vasoconstriction | 1999 |
Phenylephrine precontraction increases the sensitivity of rabbit femoral artery to serotonin by enabling 5-HT1-like receptors.
Topics: Animals; Dose-Response Relationship, Drug; Femoral Artery; In Vitro Techniques; Oxadiazoles; Phenylephrine; Piperazines; Prazosin; Rabbits; Receptors, Serotonin; Ritanserin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Specific Pathogen-Free Organisms; Sumatriptan; Vasoconstriction | 2000 |
In vivo analysis of adrenergic and serotoninergic constrictions of the rabbit saphenous vein.
Topics: Adrenergic Agents; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Anesthesia; Animals; Benzazepines; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Ergolines; Imidazoles; Indoles; Injections, Intravenous; Isoindoles; Oxadiazoles; Peripheral Nervous System; Phenylephrine; Piperazines; Prazosin; Rabbits; Receptors, Adrenergic, alpha; Receptors, Serotonin; Saphenous Vein; Serotonin; Serotonin Agents; Serotonin Receptor Agonists; Sumatriptan; Tetrahydronaphthalenes; Time Factors; Ultrasonography, Doppler; Vasoconstrictor Agents | 2000 |
Cardiovascular effects of SL65.0472, a 5-HT receptor antagonist.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Dogs; Heart Rate; Hemodynamics; Male; Piperazines; Prazosin; Quinolines; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin Antagonists; Sumatriptan; Vasoconstrictor Agents | 2001 |
Successful treatment of threatening limb loss ischemia of the upper limb caused by ergotamine. A case report and review of the literature.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Angiography; Arm; Arterial Occlusive Diseases; Ergotamine; Female; Follow-Up Studies; Humans; Ischemia; Middle Aged; Migraine Disorders; Prazosin; Serotonin Antagonists; Sumatriptan; Time Factors; Vasoconstrictor Agents | 2002 |